304 related articles for article (PubMed ID: 24648731)
1. Near-infrared quantum dots for HER2 localization and imaging of cancer cells.
Rizvi SB; Rouhi S; Taniguchi S; Yang SY; Green M; Keshtgar M; Seifalian AM
Int J Nanomedicine; 2014; 9():1323-37. PubMed ID: 24648731
[TBL] [Abstract][Full Text] [Related]
2. In-vivo imaging of oral squamous cell carcinoma by EGFR monoclonal antibody conjugated near-infrared quantum dots in mice.
Yang K; Zhang FJ; Tang H; Zhao C; Cao YA; Lv XQ; Chen D; Li YD
Int J Nanomedicine; 2011; 6():1739-45. PubMed ID: 21980236
[TBL] [Abstract][Full Text] [Related]
3. Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α.
Ceran C; Cokol M; Cingoz S; Tasan I; Ozturk M; Yagci T
BMC Cancer; 2012 Oct; 12():450. PubMed ID: 23033967
[TBL] [Abstract][Full Text] [Related]
4. Dual-Labeled Near-Infrared/(99m)Tc Imaging Probes Using PAMAM-Coated Silica Nanoparticles for the Imaging of HER2-Expressing Cancer Cells.
Yamaguchi H; Tsuchimochi M; Hayama K; Kawase T; Tsubokawa N
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27399687
[TBL] [Abstract][Full Text] [Related]
5. In vivo assessment of HER2 receptor density in HER2-positive tumors by near-infrared imaging, using repeated injections of the fluorescent probe.
Ardeshirpour Y; Hassan M; Zielinski R; Horton J; Capala J; Gandjbakhche AH; Chernomordik V
Technol Cancer Res Treat; 2014 Oct; 13(5):427-34. PubMed ID: 24000992
[TBL] [Abstract][Full Text] [Related]
6. Accurate sensitivity of quantum dots for detection of HER2 expression in breast cancer cells and tissues.
Tabatabaei-Panah AS; Jeddi-Tehrani M; Ghods R; Akhondi MM; Mojtabavi N; Mahmoudi AR; Mirzadegan E; Shojaeian S; Zarnani AH
J Fluoresc; 2013 Mar; 23(2):293-302. PubMed ID: 23212129
[TBL] [Abstract][Full Text] [Related]
7. Demonstration of Calreticulin Expression in Hamster Pancreatic Adenocarcinoma with the Use of Fluorescent Gold Quantum Dots.
Giorgakis E; Ramesh B; Kamali-Dashtarzheneh A; Fusai GK; Imber C; Tsironis D; Loizidou M
Anticancer Res; 2016 Mar; 36(3):861-7. PubMed ID: 26976972
[TBL] [Abstract][Full Text] [Related]
8. Subtype classification for prediction of prognosis of breast cancer from a biomarker panel: correlations and indications.
Chen C; Yuan JP; Wei W; Tu Y; Yao F; Yang XQ; Sun JZ; Sun SR; Li Y
Int J Nanomedicine; 2014; 9():1039-48. PubMed ID: 24591826
[TBL] [Abstract][Full Text] [Related]
9. In vivo breast cancer characterization imaging using two monoclonal antibodies activatably labeled with near infrared fluorophores.
Sano K; Mitsunaga M; Nakajima T; Choyke PL; Kobayashi H
Breast Cancer Res; 2012; 14(2):R61. PubMed ID: 22510481
[TBL] [Abstract][Full Text] [Related]
10. HER2 monoclonal antibody conjugated RNase-A-associated CdTe quantum dots for targeted imaging and therapy of gastric cancer.
Ruan J; Song H; Qian Q; Li C; Wang K; Bao C; Cui D
Biomaterials; 2012 Oct; 33(29):7093-102. PubMed ID: 22796163
[TBL] [Abstract][Full Text] [Related]
11. Bio-distribution and toxicity assessment of intravenously injected anti-HER2 antibody conjugated CdSe/ZnS quantum dots in Wistar rats.
Tiwari DK; Jin T; Behari J
Int J Nanomedicine; 2011; 6():463-75. PubMed ID: 21499435
[TBL] [Abstract][Full Text] [Related]
12. Fluorescent, Recombinant-Protein-Conjugated, Near-Infrared-Emitting Quantum Dots for in Vitro and in Vivo Dual-Color Molecular Imaging.
Tsuboi S; Jin T
Chembiochem; 2019 Feb; 20(4):568-575. PubMed ID: 30353635
[TBL] [Abstract][Full Text] [Related]
13. Quantum dot-based immunofluorescent imaging of Ki67 and identification of prognostic value in HER2-positive (non-luminal) breast cancer.
Sun JZ; Chen C; Jiang G; Tian WQ; Li Y; Sun SR
Int J Nanomedicine; 2014; 9():1339-46. PubMed ID: 24648732
[TBL] [Abstract][Full Text] [Related]
14. Predictive diagnosis of the risk of breast cancer recurrence after surgery by single-particle quantum dot imaging.
Gonda K; Miyashita M; Higuchi H; Tada H; Watanabe TM; Watanabe M; Ishida T; Ohuchi N
Sci Rep; 2015 Sep; 5():14322. PubMed ID: 26392299
[TBL] [Abstract][Full Text] [Related]
15. Investigation of an antitumor drug-delivery system based on anti-HER2 antibody-conjugated BSA nanoparticles.
Zhang N; Zhang J; Wang P; Liu X; Huo P; Xu Y; Chen W; Xu H; Tian Q
Anticancer Drugs; 2018 Apr; 29(4):307-322. PubMed ID: 29381491
[TBL] [Abstract][Full Text] [Related]
16. Passive and active targeting of quantum dots for whole-body fluorescence imaging of breast cancer xenografts.
Balalaeva IV; Zdobnova TA; Krutova IV; Brilkina AA; Lebedenko EN; Deyev SM
J Biophotonics; 2012 Nov; 5(11-12):860-7. PubMed ID: 22887708
[TBL] [Abstract][Full Text] [Related]
17. Screening of HER2 Overexpressed Breast Cancer Subtype In Vivo by the Validation of High-Performance, Long-Term, and Noninvasive Fluorescence Tracer.
Ding J; Zhou Y; Li J; Jiang L; He Z; Zhu JJ
Anal Chem; 2015 Dec; 87(24):12290-7. PubMed ID: 26598802
[TBL] [Abstract][Full Text] [Related]
18. Anti-HER2 antibody and ScFvEGFR-conjugated antifouling magnetic iron oxide nanoparticles for targeting and magnetic resonance imaging of breast cancer.
Chen H; Wang L; Yu Q; Qian W; Tiwari D; Yi H; Wang AY; Huang J; Yang L; Mao H
Int J Nanomedicine; 2013; 8():3781-94. PubMed ID: 24124366
[TBL] [Abstract][Full Text] [Related]
19. Micelle-based activatable probe for in vivo near-infrared optical imaging of cancer biomolecules.
Shimizu Y; Temma T; Hara I; Makino A; Yamahara R; Ozeki E; Ono M; Saji H
Nanomedicine; 2014 Jan; 10(1):187-95. PubMed ID: 23811292
[TBL] [Abstract][Full Text] [Related]
20. Highly sensitive single domain antibody-quantum dot conjugates for detection of HER2 biomarker in lung and breast cancer cells.
Rakovich TY; Mahfoud OK; Mohamed BM; Prina-Mello A; Crosbie-Staunton K; Van Den Broeck T; De Kimpe L; Sukhanova A; Baty D; Rakovich A; Maier SA; Alves F; Nauwelaers F; Nabiev I; Chames P; Volkov Y
ACS Nano; 2014 Jun; 8(6):5682-95. PubMed ID: 24873349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
